ChiCTR-IOR-15005942
尚未开始
/
/
/
2015-02-03
/
/
Mild clinical Alzheimer’s disease
運動訓練與工作記憶訓練對減慢輕度阿氏痴呆症長者認知能力下降之隨機對比研究
運動訓練與工作記憶訓練對減慢輕度阿氏痴呆症長者認知能力下降之隨機對比研究
運動訓練與工作記憶訓練對減慢輕度阿氏痴呆症長者認知能力下降
随机平行对照
其它
Randomized
Single-blind
Health and Medical Research Fund
/
376
/
2015-02-14
1990-01-01
/
1. Subjects from 60 to 90 years old; 2. DSM-5 diagnosis of Major Neurocognitive Disorder due to AD (22), which would satisfy the criteria for significant cognitive decline in at least one of six areas of cognition (memory, perceptual-motor, complex attention, language, executive function and social cognition) and functional disturbance, with clinical or biological features indicative of AD; 3. CDR of 1 indicating mild dementia; and 4. Ambulatory with low risk of fall as assessed by the physiotherapist (co-A).；
请登录查看1. Past history of bipolar affective disorder or psychosis; 2. Physical frailty affecting attendance to training sessions; 3. Already attending regular cognitive training; 4. History of major neurological deficit including history of stroke, or traumatic brain injury; and 5. Significant communicative impairments.；
请登录查看Department of Psychiatry, The Chinese University of Hong Kong
/
Department of Psychiatry, The Chinese University of Hong Kong的其他临床试验
Department of Psychiatry, The Chinese University of Hong Kong的其他临床试验
- Effectiveness of Digital CBT-I and BT-I combined ACT for Insomnia and Anxiety Symptoms in Youth: A Randomised Control Trial
- 定位連環透顱磁力剌激對認知障礙症患者抑鬱徵狀的療效研究
- 運動訓練與工作記憶訓練對減慢輕度阿氏痴呆症長者認知能力下降之隨機對比研究
- 個人化身心運動治療對抑鬱症及焦慮症之隨機對照臨床試驗效果研究
- A randomized controlled trial of leisure activity intervention on preservation of cognitive and everyday function in Chinese older adults with early cognitive decline
最新临床资讯
-
诺华：CFB抑制剂终止狼疮肾炎二期临床
医药笔记2026-10-17
-
泽安生物医药：实体瘤MCE启动一期临床
医药笔记2026-10-17
-
药明康德2026-10-17
-
沃森生物2026-10-16
-
罕见病信息网2026-10-16
-
武警特色医学中心2026-10-16
-
生物经纬2026-10-16
-
良医汇肿瘤资讯2026-10-16
-
BioMed科技2026-10-16
-
蒲公英资讯2026-10-16
全球药物研发中心
全球研发数据与行业前沿情报
研发动态
相关报告
政策法规
-
2026-10-26
-
2026-10-25
-
2026-10-25
-
摩熵咨询 33 51
-
摩熵咨询 20 3
-
摩熵咨询 20 10
-
颁布机构：国家药品审评中心（CDE） 2026-10-16
-
颁布机构：国家药品监督管理局药品审评中心 2026-09-28
-
颁布机构：国家药品监督管理局 2026-09-10
医药市场洞察中心
医药市场销售数据分析 · 智能洞察 · 竞争格局监测
-
医药市场销售数据分析 · 医院、实体药店、网上药店
-
市场竞争格局分析(靶点、药品类型、ATC大类)
市场动态
市场报告
政策法规
-
2026-10-23
-
2026-10-23
-
2026-10-21
-
摩熵咨询 35 83
-
摩熵咨询 28 71
-
摩熵咨询 34 47
-
颁布机构：国家药品监督管理局 2026-10-19
-
颁布机构：国家市场监督管理总局 2026-10-16
-
颁布机构：国家市场监督管理总局 2026-09-30